SAREUM HOLDINGS PLC Logo

SAREUM HOLDINGS PLC

SAR | IL

Overview

Corporate Details

ISIN(s):
GB00BMC3RJ87
LEI:
213800PKERN2DY8FFM72
Country:
United Kingdom
Address:
UNIT 2A, CB22 3FX CAMBRIDGE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Sareum Holdings PLC is a clinical-stage drug discovery and development company specializing in small molecule therapeutics. The company develops next-generation kinase inhibitors to treat autoimmune diseases and cancer. Its primary focus is on the TYK/JAK kinase cell signalling family, advancing dual inhibitors of TYK2 and JAK1, which it believes offer superior efficacy compared to single-kinase agents. The company's lead autoimmune candidate, SDC-1801, has successfully completed a Phase 1 clinical trial. Sareum's pipeline also includes a Chk1 kinase inhibitor program for oncology.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for SAREUM HOLDINGS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-20 11:01
Share Issue/Capital Change
Exercise of Warrants
English 10.5 KB
2025-08-12 08:00
Regulatory News Service
Sareum Collaboration with Receptor.AI
English 15.3 KB
2025-07-09 08:00
Share Issue/Capital Change
Exercise of Warrants
English 10.7 KB
2025-05-29 08:00
Regulatory News Service
Initiation of Toxicology Studies for SDC-1801
English 11.4 KB
2025-03-27 08:00
Director's Dealing
Director’s Dealing
English 27.8 KB
2025-03-25 08:00
Interim Report
Sareum Half-Year Report
English 133.9 KB
2025-03-13 08:15
Share Issue/Capital Change
Institutional Equity Fundraise
English 14.4 KB
2025-03-13 08:08
Regulatory News Service
Sareum Acquires Licence for SRA737
English 12.8 KB
2024-12-31 08:00
Legal Proceedings Report
Update on SRA737
English 13.5 KB
2024-12-19 17:07
Post-Annual General Meeting Information
Results of AGM
English 33.8 KB
2024-12-19 08:00
Pre-Annual General Meeting Information
AGM Statement
English 18.8 KB
2024-12-18 08:00
Regulatory News Service
Appointment of Joint Broker
English 10.1 KB
2024-12-17 10:14
Major Shareholding Notification
Holding(s) in Company
English 49.8 KB
2024-12-16 08:00
Director's Dealing
Award of Share Options
English 45.8 KB
2024-11-27 10:38
Pre-Annual General Meeting Information
Notice of AGM, Annual Report and Accounts
English 12.2 KB

Automate Your Workflow. Get a real-time feed of all SAREUM HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SAREUM HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN